Skip to main content
. Author manuscript; available in PMC: 2018 Oct 9.
Published in final edited form as: Pharmacol Res. 2017 Dec 2;129:365–374. doi: 10.1016/j.phrs.2017.11.033

Figure 3: Natural products targeting important pathways in uveal melanoma.

Figure 3:

UM is characterized by GNAQ/11 mutation in approximately 85% of cases. (A) Xanthones and statin inhibit PKC and MAPK pathways. (B) Phloretin and baicalein target Rho/Rac and YAP/TEAD. (C) Enoxolone, magnolol, and palmatine inhibit ZEB1.